CD3D is associated with immune checkpoints and predicts favorable clinical outcome in colon cancer

• Published in: Immunotherapy Vol. 12; no. 1; pp. 25 - 35
• Main Authors: Yang, Yi, Zang, Yiwen, Zheng, Chuang, Li, Zhenyang, Gu, Xiaodong, Zhou, Minwei, Wang, Zihao, Xiang, Jianbin, Chen, Zongyou, Zhou, Yiming
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.01.2020
• Subjects: Adenocarcinoma; Adenocarcinoma - immunology; Adenocarcinoma - mortality; Antigens; CD3 antigen; CD3 Complex - metabolism; CD3D; Chemokines; Clinical outcomes; COAD; Colon cancer; Colonic Neoplasms - immunology; Colonic Neoplasms - mortality; Colorectal cancer; Correlation analysis; Female; Gene Expression Regulation, Neoplastic; Gene Ontology; Genes; Humans; immune; Immune checkpoint; Immune Checkpoint Proteins - metabolism; Immunomodulation; Immunotherapy; Immunotherapy - methods; Lymphatic system; Lymphocytes; Lymphocytes T; Lymphocytes, Tumor-Infiltrating - immunology; Male; Medical prognosis; Melanoma; Metastasis; Middle Aged; Neoplasm Staging; Ontology; Proteins; Receptors, Antigen, T-Cell, alpha-beta - metabolism; Signal transduction; survival; Survival Analysis; T cell receptors; T-Lymphocytes - immunology; Thyroid cancer; Tumors; Variance analysis; COAD; immune; CD3D; survival
• ISSN: 1750-743X; 1750-7448
• DOI: 10.2217/imt-2019-0145

The T cell receptor–CD3 complex has shown great potential in tumor therapy. However, there is currently no research on CD3D in tumors. Correlation between CD3D expression and clinical parameters and immune checkpoints of of colon adenocarcinoma (COAD) were analyzed. CD3D decreased with increasing clinical stage and microsatellite status of COAD. Functional enrichment analysis revealed that CD3D is related to immune activation and regulation. Coexpression analysis indicated that CD3D is correlated with immune checkpoint and immune-infiltrated cells. Patients with higher expression of CD3D showed better clinical outcome. The findings suggest that the participation of CD3D may serve as a prognostic marker of COAD and may act as a guide in the development of immunotherapy.